Physician profile
Amy Kennedy Bindner
NPI 1477509875
$3,402.44
in general payments reported to CMS, 2019-2025
23 companies · $535 in 2025
The $535 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $388 · 2021: $505 · 2022: $325 · 2023: $463 · 2024: $704 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $673.92 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $493.91 | 2021-2025 | Azstarys |
| Tris Pharma INC | $446.57 | 2019-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $230.68 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Collegium Pharmaceutical, INC. | $221.27 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $199.42 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Ironshore Pharmaceuticals INC. | $197.16 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $167.67 | 2019-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Adlon Therapeutics L.P. | $119.01 | 2019-2021 | |
| Sanofi Pasteur INC. | $117.03 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.15 | 2019-2021 | |
| Kaleo, INC. | $77.46 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $76.43 | 2019-2024 | |
| Cranial Technologies, INC | $43.90 | 2024-2025 | Doc Band |
| Seqirus USA INC | $38.51 | 2024 | Flucelvax |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $37.79 | 2020 | |
| Sanofi-Aventis U.S. LLC | $37.63 | 2024-2025 | |
| Rhodes Pharmaceuticals L.P. | $36.06 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.16 | 2024 | Relexxii |
| Sobi, INC | $16.14 | 2019 | |
| Circassia INC. | $15.83 | 2019 | |
| Genentech USA, INC. | $14.20 | 2019 | |
| Neurelis, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Bindner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.